Back To Happy And Healthy Life . . .    The Best Place To Find The Cheapest Propecia

However interactions between the two kinds of the enterprises were frequently difficult, since they developed from the different cultures. A solution was the acquisition of the more successful biotechnology enterprises by large pharmaceutical companies. These included the following acquisition: Genentech by Hoffman Laroche, Chiron by CIBA Ciba Geigy (Novartis), Genetik-Institut by American Home of products, sphinx Biotechnologies by Lily and Affymax by Glaxo. While somewhat prominent biotechnology makes remained independently e.g. Amgen firm, connected at most the pharmaceutical industry. Prospects for an independent biotechnology industry disappeared soon. Although the difficulty of the raising of the sufficient capital of the private investors was an important reason, there is also a second explanation, which betweensingle projectandmultiproject fromthe distinction firms.AsGuedj resulted and sharp stone (2004) observes, "the problem with particular project enterprises is, which, if they have bad favorable possibilities of the investment of funds, theymay invest silence, because managers are against-striving, capital to the shareholders to return. . This conflict is weakened in an internal capital market, as far as that high-grade managers can keep capital for investment, but a more expanded distance of the projects has, in those invests "(pp. 1-2). Small biotechnology starts, which have frequently only a particular research project, continue sometimes investing capital even if prospects are relatively weak. In order to examine this affair, Guedj and sharp stone starting biotechnology enterprise compare with main enterprises the one larger number of projects have. They report that particular project enterprises were more probable, their products of phase 1 on phase of 2 attempts within a two-year period, when to shift due enterprises were. However their products were also less probable to demonstrate good results phase 2 in the attempts and less probably to move in phase 3 attempts within a three-year period. The authors interpret these discoveries as suggesting an agency problem between investors and managers for smaller, particular project enterprise, which leads frequently to Overinvestment in the research. Therefore larger, product-rich enterprises were more efficient. Although the early biotech enterprises had an advantage in their understanding of the new scientific technology, they confronted the economic hurdle of the raising of the sufficient capital to get in order to lead their research, the extensive attempts to accomplish, which were needed by FDA, and their products too market.Aswith other starts searched them originally the financing investor, although this was connected soon by contracts and grants of leading the pharmaceutical companies. In the return for to to order the necessary capital, looked for the larger companies of alliances place the national economy of research and of development 61, by which they would divide in the return of all new products, those resulted. An important characteristic of the biotechnology sector is the increasing arrangement of alliances between small starting enterprises and larger pharmaceutical companies. These alliances represent a middle soil between completely independent negotiations and the acquisition of the smaller enterprise by the larger company. Up to the nineties became the financing by the prominent pharmaceutical companies for their allies a main source of the biotechnology financing. In four years - 1994, 1995, 1997 and 1998 - the alliance financing represented more than half of the quantities, which became to receive 60% of total financing by starting biotechnology enterprises and exceeded, although it was a little lower in other years.